As Washington rushes headfirst into another massive reconciliation bill, a troubling policy proposal threatens to undermine America’s global leadership in medical innovation.
The Trump administration’s renewed effort to garner Republican support for a “Most Favored Nation” (MFN) foreign reference pricing model in the Medicaid rebate formula would strike the American free market at its core.
Monday morning, the president set a 30-day deadline for drug manufacturers to set lower prices, which Big Pharma has called “a bad deal.” We’ll see what deal indeed it is that America’s negotiator-in-chief is able to make with Congress.
Read more at Newsmax© 2025 Newsmax. All rights reserved.
